Lymphocyte-to-monocyte, platelet-to-albumin and platelet-to-lymphocyte ratios as prognostic biomarkers for neoadjuvant treatment response in rectal cancer patients.

Lymphocyte-to-monocyte ratio Platelet-to-albumin ratio Platelet-to-lymphocyte ratio Radio-chemotherapy Rectal cancer

Journal

Surgical oncology
ISSN: 1879-3320
Titre abrégé: Surg Oncol
Pays: Netherlands
ID NLM: 9208188

Informations de publication

Date de publication:
28 Aug 2024
Historique:
received: 09 06 2024
revised: 24 08 2024
accepted: 25 08 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 30 8 2024
Statut: aheadofprint

Résumé

Systemic inflammatory response (SIR) indicators are an emerging category of serum biomarkers with significant potential as prognostic and predictive factors in various types of cancers The primary focus of our study was to determine the prognostic value of the lymphocyte-to-monocyte ratio (LMR), platelet-to-albumin ratio (PLR) and platelet-to-albumin ratio (PAR) in evaluating the response to neoadjuvant treatment for patients with rectal cancer. We included 99 consecutive patients with rectal cancer which were admitted for surgery in our institution after completing a standard neoadjuvant radio-chemotherapy regimen. Several hematologic parameters, including LMR, PAR and PLR, were calculated by collecting and analyzing blood samples preoperatively. Cases were divided into groups using ROC curve analysis to determine optimal cutoff values for each of the investigated parameters. Treatment response was assessed through histopathological analysis of the resected specimens. PLR values over 215.2 were correlated with the presence of lymph node metastasis. A similar correlation was observed between PAR values over 41.89 and lymph node positivity. A significant correlation was observed between the presence of tumor budding on histopathological analysis and high-PAR values. A statistically significant correlation between a high PLR and a good response to neoadjuvant treatment was determined. High PLR values may be associated with a more favorable treatment response to neoadjuvant radio-chemotherapy. A high PAR may be associated with unfavorable histopathological characteristics. Further studies on these readily available biomarkers are required in order to validate their clinical utility.

Identifiants

pubmed: 39213835
pii: S0960-7404(24)00094-X
doi: 10.1016/j.suronc.2024.102126
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102126

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of competing interest None.

Auteurs

V Făgărășan (V)

1st Surgical Department, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012, Cluj Napoca, Romania. Electronic address: fagarasan.vlad@elearn.umfcluj.ro.

V Bințințan (V)

1st Surgical Department, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012, Cluj Napoca, Romania. Electronic address: vasile.bintintan@umfcluj.ro.

R Seicean (R)

1st Surgical Department, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012, Cluj Napoca, Romania. Electronic address: radu.seicean@umfcluj.ro.

A Caziuc (A)

1st Surgical Department, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012, Cluj Napoca, Romania. Electronic address: alexandra.caziuc@umfcluj.ro.

R AIlioaie (R)

1st Surgical Department, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012, Cluj Napoca, Romania. Electronic address: raluca.apostu@umfcluj.ro.

G Făgărășan (G)

1st Surgical Department, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012, Cluj Napoca, Romania. Electronic address: amarinei.giorgiana@elearn.umfcluj.ro.

A Ilie-Ene (A)

1st Surgical Department, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012, Cluj Napoca, Romania. Electronic address: ilieene.alexandru@elearn.umfcluj.ro.

G Dindelegan (G)

1st Surgical Department, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012, Cluj Napoca, Romania. Electronic address: george.dindelegan@umfcluj.ro.

C Căinap (C)

Department of Medical Oncology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012, Cluj-Napoca, Romania. Electronic address: calin.cainap@umfcluj.ro.

Classifications MeSH